Brain+

0,036

DKK

+11,18 %

Mindre end 1K følgere

BRAINP

First North Denmark

Biotechnology & Pharmaceuticals

Health Care

Overview

Finansielt overblik og estimater

Ownership

+11,18%

+18,02%

-23,25%

-18,93%

-10,01%

-45,23%

-96,17%

-

-97,39%

Brain + er aktiv i medicinalindustrien. Virksomheden har specialiseret sig i forskning og udvikling til behandling af demens og Alzheimers. Produktporteføljen omfatter f.eks. Kognitiv stimuleringsterapi. Forretningen drives med den største tilstedeværelse i Europa.

Markedsværdi

34,49 mio. DKK

Aktieomsætning

28,35 t DKK

Omsætning

-

EBIT %

-

P/E

-

Udbytteafkast, %

-

Finanskalender

29.4

2025

Årsrapport '24

29.5

2025

Generalforsamling '25

28.8

2025

Delårsrapport Q2'25

Alle

Selskabsmeddelelser

Eksterne analyser

ViserAlle indholdstyper

Pressemeddelelsefor 4 timer siden

Brain+ A/S: Brain+ to close first UK Care Home partnership contract with Southcare Homes Group

Pressemeddelelse19.3.2025, 13.44

Brain+ A/S: Invitation to investor webinar to present new Board Observer, sales pipeline progress and ongoing Unit Rights Issue

Pressemeddelelse19.3.2025, 07.42

Brain+ A/S: Brain+ expands its UK sales pipeline to €+500,000 in revenue and reveals Key Performance Indicators

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Selskabsmeddelelse17.3.2025, 07.59

Brain+ A/S: The subscription period in Brain+' rights issue of units begins today

Pressemeddelelse11.3.2025, 09.54

Brain+ A/S: UK care sector expert, Vishal Shah joins Brain+ as Advisor and Board Observer

Pressemeddelelse10.3.2025, 07.31

Brain+ A/S: The benefits of Ayla - your CST Assistant featured in CareTech, the healthtech media for Danish healthcare professionals

Selskabsmeddelelse6.3.2025, 07.50

Brain+ A/S: Brain+ resolves to carry out its earlier announced unit rights issue of up to approximately DKK 16 million

Selskabsmeddelelse12.2.2025, 11.02

Brain+ A/S - Minutes of Extraordinary General Meeting

Pressemeddelelse30.1.2025, 12.47

Brain+ A/S: Invitation to Investor Webinar to update on sales outlook, restructuring and secured funding

Selskabsmeddelelse28.1.2025, 17.33

Brain+ A/S - Notice of Extraordinary General Meeting

Selskabsmeddelelse22.1.2025, 18.30

Brain+ A/S: Brain+ restructures to reduce OPEX by 35%, maintaining €1M ARR target for end 2025 and now expecting break-even by mid-2026, and announces 50% secured intended Rights Issue

Selskabsmeddelelse31.12.2024, 13.30

Brain+ A/S: Brain+ announces change of Certified Advisor

Pressemeddelelse10.12.2024, 07.45

Brain+ A/S: Brain+ invites to investor webinar to update on UK commercial pipeline and status

Pressemeddelelse5.12.2024, 07.51

Brain+ A/S: Brain+ secures its first multi-year sales contract for Ayla - your CST Assistant with Syddjurs municipality

Pressemeddelelse21.11.2024, 14.30

Brain+ A/S: Invitation to Investor Webinar on Monday 25th of November at 15:30: Update on commercial status and new opportunities

Pressemeddelelse1.11.2024, 10.57

Brain+ A/S: Brain+ closes new Danish municipality sales contract on Ayla - your CST Assistant

Pressemeddelelse21.10.2024, 09.54

Brain+ A/S: Brain+ progresses UK commercial outreach and hosts the first of a series of webinars on the value of Cognitive Stimulation Therapy

Pressemeddelelse11.10.2024, 07.04

Brain+ A/S: Brain+ unveils new visual brand and website to elevate its Ayla Dementia Care solutions

Selskabsmeddelelse7.10.2024, 09.50

Brain+ A/S: Brain+ announces first day of trading in new shares from the TO 4 warrant exercise and the related directed issue

Pressemeddelelse2.10.2024, 08.32

Brain+ A/S: Brain+ launches Ayla - your CST Assistant into the UK dementia market

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.